(Total Views: 402)
Posted On: 07/16/2025 7:04:58 PM
Post# of 155727
Re: Buddyboy20 #155164
"Weekly Leronlimab treatment in a chronically SIV-infected macaque led to increased CCR5+CD4+ T cells levels and fully suppressed plasma viremia, both concomitant with full CCR5 RO on peripheral blood CD4+ T cells, demonstrating that CCR5+CD4+ T cells were protected from viral replication by Leronlimab binding.
Finally, we extended these results to Leronlimab-treated humans and found that weekly 700 mg Leronlimab led to complete CCR5 RO on peripheral blood CD4+ T cells and a statistically significant increase in CCR5+CD4+ T cells in peripheral blood.
Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes"
Pages 1 - 2 of Nov. 19th, 2021
https://www.cytodyn.com/publications?category=HIV
__<
Yes sir -- Dr. Sacha being one of the authors, current mgt knows of the very large opportunity too....
Assay test was designed with blood from 8 people in our Long Haulers trial. Having LL effect to CD4+ T Cell results too.
Our past largest Hiv trial of 556 enrolled, has FDA mandated retained samples until Dec. 7th, 2025.
Would not be surprised if Cytodyn has re-sampled a qualifying size of CD4+ T Cells from that 556
Actually they should have already completed that with the FDA. If so, then waiting on a RECOVER-LC yes or no.
Either way, expecting great CD4+ T Cells news due to those retained Hiv samples -- fitting due to how significant Hiv was the outsized focus for yrs.
Finally, we extended these results to Leronlimab-treated humans and found that weekly 700 mg Leronlimab led to complete CCR5 RO on peripheral blood CD4+ T cells and a statistically significant increase in CCR5+CD4+ T cells in peripheral blood.
Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes"
Pages 1 - 2 of Nov. 19th, 2021
https://www.cytodyn.com/publications?category=HIV
__<
Yes sir -- Dr. Sacha being one of the authors, current mgt knows of the very large opportunity too....
Assay test was designed with blood from 8 people in our Long Haulers trial. Having LL effect to CD4+ T Cell results too.
Our past largest Hiv trial of 556 enrolled, has FDA mandated retained samples until Dec. 7th, 2025.
Would not be surprised if Cytodyn has re-sampled a qualifying size of CD4+ T Cells from that 556
Actually they should have already completed that with the FDA. If so, then waiting on a RECOVER-LC yes or no.
Either way, expecting great CD4+ T Cells news due to those retained Hiv samples -- fitting due to how significant Hiv was the outsized focus for yrs.
(4)
(0)
